Two doctors sued Teva for failing to acknowledge their contributions and demanded to be compensated with royalties stemming from the new version of copaxone.
Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020(photo credit: SIVAN FARAG)ByYONAH JEREMY BOBUpdated:
